(NVST) Envista Holdings - Ratings and Ratios
Dental Implants, Aligners, Digital Imaging, Restoratives, Infection Control
NVST EPS (Earnings per Share)
NVST Revenue
Description: NVST Envista Holdings
Envista Holdings Corp (NYSE:NVST) is a leading global provider of dental products and technologies, operating through two main segments: Specialty Products & Technologies, and Equipment & Consumables. The company offers a comprehensive range of products, including dental implant systems, orthodontic solutions, digital imaging systems, and infection prevention products, under various brands such as Nobel Biocare, Ormco, and Kerr.
From a financial perspective, Envista Holdings Corp has a market capitalization of approximately $3.38 billion, with a forward price-to-earnings ratio of 19.80. The companys return on equity (ROE) is currently negative, indicating that it may be experiencing challenges in generating profits. Key performance indicators (KPIs) to monitor include revenue growth, gross margin, and operating cash flow. For instance, a rising gross margin could indicate improving profitability, while increasing operating cash flow could suggest a strengthening financial position.
In terms of valuation, Envista Holdings Corps price-to-sales ratio and enterprise value-to-EBITDA ratio can provide insights into its relative valuation compared to industry peers. Additionally, metrics such as days sales outstanding (DSO) and inventory turnover can help assess the companys working capital management and operational efficiency. A thorough analysis of these KPIs can help investors and analysts better understand the companys financial health and growth prospects.
To further evaluate Envista Holdings Corps investment potential, it is essential to examine its competitive positioning, product pipeline, and strategic initiatives. For example, the companys focus on digital dentistry and innovative products, such as DTX Studio Implant and Spark clear aligners, may be driving growth and market share gains. By analyzing these factors, investors can gain a more comprehensive understanding of the companys prospects and make informed investment decisions.
NVST Stock Overview
| Market Cap in USD | 3,591m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2019-09-18 |
NVST Stock Ratings
| Growth Rating | -33.4% |
| Fundamental | 46.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -6.84% |
| Analyst Rating | 3.29 of 5 |
NVST Dividends
Currently no dividends paidNVST Growth Ratios
| Growth Correlation 3m | 79.5% |
| Growth Correlation 12m | 6.6% |
| Growth Correlation 5y | -79% |
| CAGR 5y | -14.58% |
| CAGR/Max DD 3y | -0.22 |
| CAGR/Mean DD 3y | -0.30 |
| Sharpe Ratio 12m | -0.67 |
| Alpha | 0.02 |
| Beta | 0.738 |
| Volatility | 35.30% |
| Current Volume | 1938.8k |
| Average Volume 20d | 1426.1k |
| Stop Loss | 20.1 (-4.2%) |
| Signal | -0.82 |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (53.8m TTM) > 0 and > 6% of Revenue (6% = 153.2m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -0.72pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 44.69% (prev 39.49%; Δ 5.21pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 292.1m > Net Income 53.8m (YES >=105%, WARN >=100%) |
| Net Debt (485.6m) to EBITDA (258.8m) ratio: 1.88 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.44 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (169.9m) change vs 12m ago -1.28% (target <= -2.0% for YES) |
| Gross Margin 54.68% (prev 54.75%; Δ -0.07pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 45.99% (prev 46.59%; Δ -0.60pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.17 (EBITDA TTM 258.8m / Interest Expense TTM 39.1m) >= 6 (WARN >= 3) |
Altman Z'' 1.03
| (A) 0.20 = (Total Current Assets 1.93b - Total Current Liabilities 793.9m) / Total Assets 5.66b |
| (B) -0.08 = Retained Earnings (Balance) -443.0m / Total Assets 5.66b |
| (C) 0.03 = EBIT TTM 163.2m / Avg Total Assets 5.55b |
| (D) -0.22 = Book Value of Equity -564.8m / Total Liabilities 2.53b |
| Total Rating: 1.03 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 46.14
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield 6.51% = 3.25 |
| 3. FCF Margin 10.10% = 2.53 |
| 4. Debt/Equity 0.47 = 2.39 |
| 5. Debt/Ebitda 5.72 = -2.50 |
| 6. ROIC - WACC (= -3.92)% = -4.90 |
| 7. RoE 1.77% = 0.15 |
| 8. Rev. Trend 0.17% = 0.01 |
| 9. EPS Trend -75.90% = -3.79 |
What is the price of NVST shares?
Over the past week, the price has changed by +1.01%, over one month by +1.01%, over three months by +13.84% and over the past year by +10.42%.
Is Envista Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NVST is around 19.02 USD . This means that NVST is currently overvalued and has a potential downside of -9.34%.
Is NVST a buy, sell or hold?
- Strong Buy: 3
- Buy: 0
- Hold: 10
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the NVST price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21.4 | 2.1% |
| Analysts Target Price | 21.4 | 2.1% |
| ValueRay Target Price | 20.8 | -1% |
Last update: 2025-09-13 04:39
NVST Fundamental Data Overview
CCE Cash And Equivalents = 1.11b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 67.5313
P/E Forward = 16.9779
P/S = 1.4067
P/B = 1.0996
Beta = 0.995
Revenue TTM = 2.55b USD
EBIT TTM = 163.2m USD
EBITDA TTM = 258.8m USD
Long Term Debt = 1.45b USD (from longTermDebt, last quarter)
Short Term Debt = 36.1m USD (from shortTermDebt, last quarter)
Debt = 1.48b USD (Calculated: Short Term 36.1m + Long Term 1.45b)
Net Debt = 485.6m USD (from netDebt column, last quarter)
Enterprise Value = 3.96b USD (3.59b + Debt 1.48b - CCE 1.11b)
Interest Coverage Ratio = 4.17 (Ebit TTM 163.2m / Interest Expense TTM 39.1m)
FCF Yield = 6.51% (FCF TTM 257.9m / Enterprise Value 3.96b)
FCF Margin = 10.10% (FCF TTM 257.9m / Revenue TTM 2.55b)
Net Margin = 2.11% (Net Income TTM 53.8m / Revenue TTM 2.55b)
Gross Margin = 54.68% ((Revenue TTM 2.55b - Cost of Revenue TTM 1.16b) / Revenue TTM)
Tobins Q-Ratio = -7.01 (set to none) (Enterprise Value 3.96b / Book Value Of Equity -564.8m)
Interest Expense / Debt = 0.54% (Interest Expense 8.00m / Debt 1.48b)
Taxrate = 35.14% (14.3m / 40.7m)
NOPAT = 105.9m (EBIT 163.2m * (1 - 35.14%))
Current Ratio = 2.44 (Total Current Assets 1.93b / Total Current Liabilities 793.9m)
Debt / Equity = 0.47 (Debt 1.48b / last Quarter total Stockholder Equity 3.14b)
Debt / EBITDA = 5.72 (Net Debt 485.6m / EBITDA 258.8m)
Debt / FCF = 5.74 (Debt 1.48b / FCF TTM 257.9m)
Total Stockholder Equity = 3.05b (last 4 quarters mean)
RoA = 0.95% (Net Income 53.8m, Total Assets 5.66b )
RoE = 1.77% (Net Income TTM 53.8m / Total Stockholder Equity 3.05b)
RoCE = 3.63% (Ebit 163.2m / (Equity 3.05b + L.T.Debt 1.45b))
RoIC = 2.37% (NOPAT 105.9m / Invested Capital 4.46b)
WACC = 6.29% (E(3.59b)/V(5.07b) * Re(8.74%)) + (D(1.48b)/V(5.07b) * Rd(0.54%) * (1-Tc(0.35)))
Shares Correlation 3-Years: -57.58 | Cagr: -0.37%
Discount Rate = 8.74% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 77.51% ; FCFE base≈269.3m ; Y1≈302.0m ; Y5≈403.0m
Fair Price DCF = 36.93 (DCF Value 6.14b / Shares Outstanding 166.2m; 5y FCF grow 14.07% → 3.0% )
EPS Correlation: -75.90 | EPS CAGR: -19.37% | SUE: 0.41 | # QB: 0
Revenue Correlation: 0.17 | Revenue CAGR: 2.87% | SUE: 3.97 | # QB: 2
Additional Sources for NVST Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle